AstraZeneca has unveiled strong 16% revenue growth for the year just gone, but price pressures from the US and China means this is expected to dip below 10% in 2025. That will make it more difficult for company to achieve its ambitious goal of hitting $80bn in revenues in 2030; there is still a long way from last year’s income of around $51bn.
AstraZeneca’s $80bn Ambition Riding On This Year’s Phase III Readouts
The company needs a string of Phase III wins this year to keep on track to reach $80bn revenues in 2030, with analysts still skeptical. Meanwhile, investors were relieved to learn that any fine related to a China corruption probe would be relatively modest.
